Why the study?
Can transcatheter aortic valve implantation be successfully performed in a patient with a failed HAART 300 aortic annuloplasty device?
Can transcatheter aortic valve implantation be successfully performed in a patient with a failed HAART 300 aortic annuloplasty device?
Transfemoral TAVI with a CoreValve Evolut R appears to be a feasible and safe option for treating patients with a failed HAART 300 aortic annuloplasty device.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for TAVI in failed HAART 300 annuloplasty; prospective studies needed before clinical adoption.
We report the first successful case, to our knowledge, of CoreValve Evolut R (Medtronic, Minneapolis, MN) implantation into a failed HAART 300 aortic annuloplasty device (BioStable Science & Engineering, TX). An 81-year-old man presented with severe symptomatic aortic regurgitation secondary to failure of the 21 mm HAART 300 device, which had been implanted 45 days previously. Transthoracic echocardiography (TTE) revealed grade 3 aortic regurgitation with central jet, without aortic valve stenosis. Because of the high risk for redo surgery, the heart team proceeded with femoral transcatheter aortic valve implantation. The 26 mm CoreValve Evolut R was deployed into the 21 mm HAART 300 device without difficulty or complications. There were no intraoperative or postoperative complications. The patient was discharged after 5 days. TTE showed a mean aortic valve gradient of 18 mmHg, with minimal paravalvular leak. Our experience suggests that CoreValve Evolut R implantation may be an attractive option in patients with failed HAART 300 aortic annuloplasty.
No takes yet. Share an insight, caveat, or question.
Gyoten et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: